Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Valar Labs has developed Vesta, the first AI-based diagnostic test that predicts treatment response to BCG therapy in bladder cancer using routine histology slides. The test was validated across 1,000+ patients from multiple continents and can identify patients likely or unlikely to respond to standard care regimens. The company’s approach generalizes across several tumor types with ongoing research and publications presented at national oncology conferences. No therapeutics are being developed.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Valar Labs.